[
  {
    "ts": null,
    "headline": "Regeneron tees up myasthenia gravis drug approval after Phase III victory",
    "summary": "If approved, the siRNA therapy will enter a highly competitive gMG market dominated by AstraZeneca’s drugs Ultomiris and Soliris.",
    "url": "https://finnhub.io/api/news?id=5ba6e7d2a006637ea4e7523d2eeb5c408d62176c9b9a5de15f0e1b67dc63a6fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756310807,
      "headline": "Regeneron tees up myasthenia gravis drug approval after Phase III victory",
      "id": 136538802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "If approved, the siRNA therapy will enter a highly competitive gMG market dominated by AstraZeneca’s drugs Ultomiris and Soliris.",
      "url": "https://finnhub.io/api/news?id=5ba6e7d2a006637ea4e7523d2eeb5c408d62176c9b9a5de15f0e1b67dc63a6fc"
    }
  },
  {
    "ts": null,
    "headline": "What Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock?",
    "summary": "Regeneron’s stock has fallen behind the broader market over the past year, but analysts see potential for growth, tempered with caution.",
    "url": "https://finnhub.io/api/news?id=85984dcf153abe545323606f8b717cf3c3e538bcdd3806b9614d8ffc8a73d3b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756300506,
      "headline": "What Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock?",
      "id": 136539793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron’s stock has fallen behind the broader market over the past year, but analysts see potential for growth, tempered with caution.",
      "url": "https://finnhub.io/api/news?id=85984dcf153abe545323606f8b717cf3c3e538bcdd3806b9614d8ffc8a73d3b3"
    }
  },
  {
    "ts": null,
    "headline": "Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic",
    "summary": "Dyslipidemia, linked to elevated cardiovascular disease risk, is benefiting from advancements in lipid profiling and genetic testing, catalyzing demand for personalized treatments. Statins dominate therapy, supported by PCSK9 inhibitors and RNA-based medicines. However, challenges like medication non-compliance, side effects, and high drug costs, especially in lower-income regions, impede market expansion. Yet, proactive government initiatives and heightened research funding are improving treatm",
    "url": "https://finnhub.io/api/news?id=459030ebf78534849e2c06f68d0a59a57cd09453cecbb0b13f1d5e1fe019216b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756285140,
      "headline": "Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic",
      "id": 136536358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Dyslipidemia, linked to elevated cardiovascular disease risk, is benefiting from advancements in lipid profiling and genetic testing, catalyzing demand for personalized treatments. Statins dominate therapy, supported by PCSK9 inhibitors and RNA-based medicines. However, challenges like medication non-compliance, side effects, and high drug costs, especially in lower-income regions, impede market expansion. Yet, proactive government initiatives and heightened research funding are improving treatm",
      "url": "https://finnhub.io/api/news?id=459030ebf78534849e2c06f68d0a59a57cd09453cecbb0b13f1d5e1fe019216b"
    }
  },
  {
    "ts": null,
    "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
    "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea",
    "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756284600,
      "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
      "id": 136536324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea",
      "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be"
    }
  }
]